Indonesia sales of prescription and OTC drugs expected to reach $5.89 billion in 2014

Indonesia is occupying 11th place, out of the 17 regional markets surveyed in the Asia Pacific region by Business Monitor International’s Business Environment Rating matrix for fourth-quarter 2010. The country's pharmaceutical rating has risen to 48.9, marking a slight increase over the previous quarter. However, it is still lower than the average for the region, which stands at 52.3.

The main drawbacks to investment in Indonesia include corruption, low per-capita spending on pharmaceuticals and a small proportion of the elderly in the country. On the other hand, factors such annual growth of its pharmaceutical market, coupled with rising population numbers and a relatively solid political and economic base are expected to encourage multinationals to invest in the country despite a risky operating environment.

Over 10% pharma CAGR forecast